Table 2.
Reasons for no adjuvant therapy | Total N = 102 (%) |
---|---|
Fear of adverse events of imatinib | 39 (38.2%) |
Economic reasons | 26 (25.5%) |
Advanced age | 20 (19.6%) |
Patient refusal unknown | 20 (19.6%) |
Comorbidities | 15 (14.7%) |
Doubts for evidences of OS | 10 (9.8%) |
Re-review results of central pathology | 3 (2.9%) |
Fear of resistant mutations | 2 (2.0%) |
Poor PS | 1 (1.0%) |
Others | 2 (2.0%) |